Efficacy and safety by subgroup at week 48 after switch to doravirine/islatravir (100 mg/0.75 mg) once daily in two phase 3 trials

Conference Reports for NATAP

19th European AIDS Conference
October 18th-21st , 2023
Warsaw, Poland


Efficacy and safety by subgroup at week 48 after switch to doravirine/islatravir (100 mg/0.75 mg) once daily in two phase 3 trials

	EACS 2023 Oct 18-21 Warsaw